Pharma in Focus
Email Address Sign-Up

Australia's most trusted source of pharma news


Off-label move a legal nightmare

Posted 23 February 2021

The TGA's recent decision to put the feelers out on the repurposing of medicines has sparked warnings it could "unravel the pharma industry in Australia" according to legal experts. 

Three options have been put forward by the TGA to encourage pharma companies, industry bodies and patient groups to seek registration of new indications but each could result in significant legal, commercial and economic consequences for industry, according to specialist law firm, Pearce IP.

Looks like you've lost your access to Pharma in Focus. To restore access or update your subscription, click here

Approvals Action
Pfizer vs Humira
Adds to a growing list of adalimumab biosims
Top of the Hill
How not to reform the PBAC
In the face of deep change, is piecemeal enough?
Special Report
Aust Covid Vaccine Tracker
UPDATE: Distribution of two mRNA vaccines overseas